Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have received a consensus rating of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $58.83.

A number of brokerages have commented on ESTA. Stephens reaffirmed an “overweight” rating and set a $68.00 target price on shares of Establishment Labs in a research note on Wednesday, August 7th. Citigroup upped their price objective on Establishment Labs from $45.00 to $50.00 and gave the company a “neutral” rating in a report on Tuesday, October 1st. BTIG Research raised their target price on Establishment Labs from $62.00 to $65.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Finally, JPMorgan Chase & Co. reduced their target price on Establishment Labs from $61.00 to $50.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th.

Establishment Labs Stock Down 0.9 %

ESTA stock opened at $41.91 on Monday. The company has a current ratio of 4.44, a quick ratio of 2.91 and a debt-to-equity ratio of 4.30. The firm has a 50-day moving average of $42.94 and a two-hundred day moving average of $46.58. Establishment Labs has a 12 month low of $16.96 and a 12 month high of $60.12. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -13.35 and a beta of 1.20.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). The company had revenue of $44.12 million during the quarter, compared to analyst estimates of $43.10 million. Establishment Labs had a negative net margin of 54.97% and a negative return on equity of 220.67%. Establishment Labs’s revenue for the quarter was down 9.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.65) EPS. As a group, analysts forecast that Establishment Labs will post -2.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Establishment Labs

A number of institutional investors have recently modified their holdings of the company. Hood River Capital Management LLC acquired a new stake in Establishment Labs during the 2nd quarter worth approximately $43,000. Nkcfo LLC purchased a new position in Establishment Labs in the second quarter valued at $227,000. Concurrent Investment Advisors LLC acquired a new position in Establishment Labs during the 1st quarter worth $263,000. SG Americas Securities LLC acquired a new position in Establishment Labs during the 2nd quarter worth $303,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in Establishment Labs during the 2nd quarter worth about $373,000. 72.91% of the stock is owned by institutional investors and hedge funds.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.